Neuromyelitis Optica Spectrum Disorder (NMOSD) is an aggressive autoimmune condition characterized by a high-intensity “cytokine storm” and massive oxidative stress that targets the central nervous system (CNS). While traditional therapies focus on immune suppression, the VARS Triad—comprised of patented and patent-pending biotech biologicals (VARS Glutathione, VARS SOD, and VARS Catalase)—presents a transformative approach to treating the disease at the cellular and metabolic levels.
1. The Root Causes: Beyond Autoantibodies
In NMOSD, the primary trigger is the production of AQP4-IgG antibodies. However, the true “root cause” of the physical disability is the secondary cascade:
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.